BioVersys AG (SWX:BIOV)
Switzerland · Delayed Price · Currency is CHF 28.50
-0.10 (-0.35%)
At close: Apr 1, 2026
BioVersys AG Company Description
BioVersys AG researches and develops antimicrobial drugs for bacterial infections.
It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections.
The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S.
aureus; and BV500 for non-tuberculous mycobacteria infections. It has a research and license option agreement with Shionogi & Co., Ltd. to develop ansamycin leads from the BV500 program into clinical candidates.
The company was founded in 2008 and is based in Basel, Switzerland.
BioVersys AG
| Country | Switzerland |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Marc Gitzinger |
Contact Details
Address: Hochbergerstrasse 60c Basel, 4057 Switzerland | |
| Phone | 41 61 551 51 20 |
| Website | bioversys.com |
Stock Details
| Ticker Symbol | BIOV |
| Exchange | SIX Swiss Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CHF |
| ISIN Number | CH0210362643 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Marc Gitzinger | Chief Executive Officer, Co-founder and Director |
| Hernan Santiago Levett CPA | Chief Financial Officer |
| Dr. Daniel Ritz | Chief Scientific Officer |
| Fiona Gao EMBA, L.L.M. | Head of Legal |
| Philipp Schmid | Head of Finance |
| Dr. Jonathan James Butcher | Head of Business Development and Alliance Management |
| Dr. Glenn E. Dale | Chief Development Officer |
| Dr. Jurgen Jager | Head of Chemistry, Manufacturing and Controls |
| Dr. Alessia Michelotti | Head of Chemistry |
| Dr. Marija Miljkovic | Head of Laboratory |